RxDoctor Payments Data

Parimalkumar Chaudhari, MD

Critical Care Medicine · Lake Mary, FLNPI 1689958266

Payments from drug & device makers

$1,650in general payments, 2019–2025

Across 95 payments — averaging $17.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$463
  • GSK$399
  • Boehringer Ingelheim$130
  • Philips North America LLC$126
  • Regeneron Healthcare Solutions, Inc.$91
  • Sanofi$48
  • plus $392 from 14 others

What the payments were for

  • Food & beverage$1,59997%
  • Education$513%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,650 in reported general payments places this provider in the 75th percentile of 618 critical care medicine providers in Florida.

See all critical care medicine providers in Florida

Medicare billing

Part B allowed, 2024
$89,609
Medicare patients
375
Services billed
886

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter309$233,146
FasenraBenralizumab11$61,901
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr45$25,095
Breo ElliptaFluticasone/Vilanterol50$22,433
Spiriva RespimatTiotropium Bromide29$19,571
Breztri AerosphereBudesonide/Glycopyr/Formoterol27$17,294
Stiolto RespimatTiotropium Br/Olodaterol Hcl27$13,459
SymbicortBudesonide/Formoterol Fumarate40$10,622
Pirfenidone12$9,704
Fluticasone-SalmeterolFluticasone Propion/Salmeterol63$9,061
Wixela InhubFluticasone Propion/Salmeterol53$6,605
Advair HfaFluticasone Propion/Salmeterol15$6,596
Albuterol Sulfate HfaAlbuterol Sulfate236$6,469
Incruse ElliptaUmeclidinium Bromide12$4,879
DuleraMometasone/Formoterol13$4,467

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$399$285,552416 claims
AstraZenecaFasenra, Breztri Aerosphere, Symbicort$463$89,81878 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$130$33,02956 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 618 critical care medicine providers in Florida.

Other critical care medicine in Lake Mary

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →